BioXcel Therapeutics is trading at $0.76, down -5.86%, after extending its liquidity-event deadline.
- On August 24, BioXcel Therapeutics amended its credit agreement, moving the deadline from August 21 to August 28, 2026.
- The company must repay lenders or secure an acceptable alternative-capital transaction, underscoring ongoing financing pressure.
- Recent earnings weakness and lender-obligation concerns weigh on the stock; major indexes moved modestly, making the mixed broader market unlikely to be the primary driver.